Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HP-5000
- Development stage
- Unknown
- Lead developer
- Noven Pharmaceuticals
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Administration
- Topical
01
Overview
HP-5000 is a topical patch containing Diclofenac Sodium, a nonsteroidal anti-inflammatory drug (NSAID). Developed by Noven Pharmaceuticals, Inc. and Hisamitsu Pharmaceutical, it is designed to alleviate pain and inflammation by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. The drug has undergone studies to evaluate its potential for skin irritation and sensitization, and has been investigated for the treatment of osteoarthritis pain of the knee.
- Other names
- HP-5000 Topical PatchHP5000 Topical PatchHP 5000 Topical PatchDiclofenac Sodium Topical Systempain relief and anti-inflammatory patch
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on HP-5000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HP-5000.